Pharmaxis Ltd's (ASX:PXS) (FRA:UUD) CEO Gary Phillips tells Proactive's Andrew Scott its drug PXS-5505 will be the focus of a new study, funded by a grant from the Charlie Teo Foundation, looking at an aggressive and deadly form of brain cancer. The drug, which has commenced a phase 1/2a clinical trial for the rare bone marrow cancer myelofibrosis, will now enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.
Pharmaxis drug to be focus of new brain cancer study with grant from Charlie Teo Foundation
